GRAIL, Inc.

GRAIL, Inc. is an American biotechnology company headquartered in Menlo Park, California, dedicated to the early detection of cancer. Its mission is to alleviate the global burden of cancer by identifying the disease in its earliest, potentially more treatable and curable stages. The company leverages next-generation sequencing, population-scale clinical studies, and advanced machine learning to achieve this goal.

The company's primary product is the Galleri test, a multi-cancer early detection (MCED) blood test. This innovative test is designed to screen for over 50 types of cancer before symptoms manifest, including many for which no recommended screening tests currently exist. GRAIL operates within the biotechnology and oncology market segments, focusing on transforming cancer screening.

GRAIL, Inc. became an independent publicly traded company on Nasdaq under the ticker "GRAL" in June 2024, following its spin-off from Illumina due to regulatory mandates. In January 2026, the company completed the submission of its Premarket Approval (PMA) application for the Galleri test to the U.S. Food and Drug Administration. Josh Ofman, MD, MSHS, was appointed as the new CEO in March 2026. The company aims to establish a new standard of care in cancer screening, having reported over 180,000 commercial Galleri tests sold as of March 2024.